Price Break: Cigna Welcomes Trio of Discounted Biosimilars to Preferred Drug Roster

July 11, 2023

What You Need to Know: 

  • Cigna Group’s unit, Express Scripts, is adding three biosimilar versions of AbbVie’s arthritis treatment Humira to its preferred drugs list.
  • Reuters explains that “The biosimilars include Hyrimoz and an unbranded version of Humira from Swiss drugmaker Novartis’ (NOVN.S) Sandoz generics division, as well as German drugmaker Boehringer Ingelheim’s Cyltezo.”
  • Sandoz announced its unbranded biosimilar will be priced at an 81% discount to Humira’s current market price of $6,922 per month and Hyrimoz at a 5% discount.
  • Boehringer Ingelheim plans to launch Cyltezo at 5% – 7% below the Humira list price.
  • Express Scripts voiced that they will include these biosimilars in the formulary or drug reimbursement list.
  • There is no information on whether patients will have the same access to Sandoz’s lower-priced biosimilar. Patients may have to pay higher out-of-pocket rates or meet specific criteria to access the cheaper, unbranded biosimilar.
  • Available starting in July, these biosimilars increase competition for Humira, joining Amgen’s Amjevita and others on Express Scripts’ reimbursement list.

Source: Reuters, July 10th, 2023

Share This Story!